Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite gains on study data for liver cancer therapy

Dec. 28, 2022 8:16 AM ETCan-Fite BioPharma Ltd. (CANF)

By: Dulan Lokuwithana, SA News Editor

Israel-based Can-Fite BioPharma (NYSE:CANF) added ~13% pre-market Wednesday after the company shared latest findings on its liver cancer therapy Namodenoson ahead of two investor conferences early next year.

An experimental oral therapy, Namodenoson is targeted at hepatocellular carcinoma, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The update relates to its studies on hepatocellular carcinoma (HCC), the commonest form of cancer, where the market size is expected to reach $3.8B by 2027 in G8 countries, according to data from Delveinsight.

The company said that its presentation at the JP Morgan healthcare conference in January and at the BI0-CEO investor conference in February would include data to compare the response of liver cancer patients to those with the most advanced liver cancer HCC Child-Pugh B (CPB).

The presentation will also contain the latest data on a CPB patient who remains clear of cancer six years after Namodenoson therapy. Can-Fite’s (CANF) Phase 3 pivotal liver cancer study for Namodenoson is now open for enrollment.

In August, Can-Fite (CANF) shares gained after the company announced that Romania approved Namodenoson for compassionate use in advanced liver cancer.